REVIEW
Treatment of acute myeloid leukemia in children: A practical perspective
Grace Egan,
Yogi Chopra,
Stephanie Mourad,
Kuang-Yueh Chiang,
Johann Hitzler,
Grace Egan
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorYogi Chopra
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorStephanie Mourad
Division of Haematology/Oncology, Montreal Children's Hospital, Montreal, QC, Canada
Search for more papers by this authorKuang-Yueh Chiang
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorCorresponding Author
Johann Hitzler
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Developmental and Stem Cell Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
Correspondence
Johann Hitzler, Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1×8, Canada.
Email: [email protected]
Search for more papers by this authorGrace Egan,
Yogi Chopra,
Stephanie Mourad,
Kuang-Yueh Chiang,
Johann Hitzler,
Grace Egan
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorYogi Chopra
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorStephanie Mourad
Division of Haematology/Oncology, Montreal Children's Hospital, Montreal, QC, Canada
Search for more papers by this authorKuang-Yueh Chiang
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Search for more papers by this authorCorresponding Author
Johann Hitzler
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Developmental and Stem Cell Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada
Correspondence
Johann Hitzler, Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1×8, Canada.
Email: [email protected]
Search for more papers by this authorAbstract
Pediatric acute myeloid leukemia (AML) is a heterogeneous disease that requires a multifaceted treatment approach. Although outcomes for low-risk AML have improved significantly over recent decades, high-risk AML continues to be associated with an adverse prognosis. Recent advances in molecular diagnostics, risk stratification, and supportive care have contributed to improvements in outcomes in pediatric AML. Targeted approaches, for example, the use of tyrosine kinase inhibitors to treat FLT3-ITD AML, offer promise and are currently undergoing clinical investigation in pediatric patients. New approaches to hematopoietic stem cell transplantation, including the use of haploidentical donors, are significantly expanding donor options for patients with high-risk AML. This review provides an overview of recent advances in the treatment of pediatric AML that are likely to have clinical impact and reshape the standard of care.
CONFLICTS OF INTEREST
None of the authors has a conflict of interest to declare.
REFERENCES
- 1Smith M, Gloeckler Ries LA, Gurney JG, Ross JA. Leukemia. In: LAG Ries, MA Smith, JG Gurney, M Linet, T Tamra, JL Young, GR Bunin, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Pub. No. 99-4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
- 2Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14): 1663-1669.
- 3Gibson BES, Sauer MG, Amrolia P. Acute myeloid leukemia in children. In: E Carreras, C Dufour, M Mohty, N Kröger, eds. The EBMT Handbook. Springer International Publishing; 2019: 523-530.
10.1007/978-3-030-02278-5_70 Google Scholar
- 4Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012; 119(25): 5980-5988.
- 5Klein K, Kaspers G, Harrison CJ, et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)-AML: results from an international retrospective study by the International Berlin-Frankfurt-Munster Study Group. J Clin Oncol. 2015; 33(36): 4247-4258.
- 6Meshinchi S, Stirewalt DL, Alonzo TA, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 2003; 102(4): 1474-1479.
- 7Goemans BF, Zwaan ChM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005; 19(9): 1536-1542.
- 8Shih L-Y, Liang D-C, Huang C-F, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008; 22(2): 303-307.
- 9Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010; 115(12): 2372-2379.
- 10Badr P, Elsayed GM, Eldin DN, Riad BY, Hamdy N. Detection of KIT mutations in core binding factor acute myeloid leukemia. Leuk Res Rep. 2018; 10: 20-25.
- 11Manara E, Basso G, Zampini M, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017; 31(1): 18-25.
- 12Tarlock K, Alonzo TA, Wang Yi-C, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019; 25(16): 5038-5048.
- 13Shimada A. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006; 107(5): 1806-1809.
- 14Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006; 108(12): 3654-3661.
- 15Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007; 110(4): 1262-1270.
- 16Staffas A, Kanduri M, Hovland R, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011; 118(22): 5905-5913.
- 17Eidenschink Brodersen L, Alonzo TA, Menssen AJ, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. Leukemia. 2016; 30(10): 2077-2080.
- 18Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010; 28(16): 2674-2681.
- 19Von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010; 28(16): 2682-2689.
- 20Brown P, Mcintyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007; 110(3): 979-985.
- 21Hollink IHIM, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009; 23(2): 262-270.
- 22Xu Lu-H, Fang J-P, Liu Y-C, Jones AI, Chai Li. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia. Blood Cancer J. 2020; 10(1): 1.
- 23Matsuo H, Kajihara M, Tomizawa D, et al. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer J. 2014; 4:e226.
- 24Hollink IHIM, Van Den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011; 118(13): 3645-3656.
- 25Georgi J-A, Taube F, Kramer M, et al. Differences between CEBPA bZIP and TAD mutations and their effect on outcome—an analysis in 4578 patients with acute myeloid leukemia. Blood. 2016; 128(22): 283-283.
- 26Gröschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010; 28(12): 2101-2107.
- 27Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3): 354-365.
- 28Dumezy F, Renneville A, Mayeur-Rousse C, Nibourel O, Labis E, Preudhomme C. Acute myeloid leukemia with translocation t(3;5): new molecular insights. Haematologica. 2013; 98(4): e52-4.
- 29Sandahl JD, Coenen EA, Forestier E, et al. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014; 99(5): 865-872.
- 30Barrett R, Morash B, Roback D, Pambrun C, Marfleet L, Ketterling RP, et al. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. Pediatr Blood Cancer. 2017; 64(8). doi: 10.1002/pbc.26450.
- 31Coenen EA, Zwaan CM, Reinhardt D, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 2013; 122(15): 2704-2713.
- 32Noort S, Zimmermann M, Reinhardt D, et al. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM study group. Blood. 2018; 132(15): 1584-1592.
- 33Gruber TA, Larson Gedman A, Zhang J, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012; 22(5): 683-697.
- 34Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3-GLIS2-positive acute myeloid leukaemia: a peculiar paediatric entity. British J Haematol. 2019; 184(3): 337-347.
- 35Masetti R, Pigazzi M, Togni M, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013; 121(17): 3469-3472.
- 36Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009; 114(12): 2489-2496.
- 37Akiki S, Dyer SA, Grimwade D, et al. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosomes Cancer. 2013; 52(11): 1053-1064.
- 38Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013; 52(7): 683-693.
- 39Struski S, Lagarde S, Bories P, et al. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia. 2017; 31(3): 565-572.
- 40Hirsch B, Alonzo TA, Gerbing RB, Kahwash S, Heerema-McKenney A, Aplenc R, et al. Abnormalities of 12p are associated with high-risk acute myeloid leukemia: a Children's Oncology Group Report. Blood. 2013; 122(21): 612.
- 41De Rooij J, Beuling E, Fornerod M, et al. ETV6 aberrations are a recurrent event in pediatric acute myeloid leukemia with poor clinical outcome. Blood. 2014; 124(21): 1012-1012.
10.1182/blood.V124.21.1012.1012 Google Scholar
- 42Johnston DL, Alonzo TA, Gerbing RB, et al. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013; 60(12): 2073-2078.
- 43Ries RE, Leonti AR, Triche TJ, et al. Structural variants involving MLLT10/AF10 are associated with adverse outcome in AML regardless of the partner gene – a COG/Tpaml study. Blood. 2019; 134(Supplement_1): 461.
- 44Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001; 97(1): 89-94.
- 45Cooper TM, Ries RE, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, et al. Revised risk stratification criteria for children with newly diagnosed acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2017; 130(Supplement 1): 407.
- 46Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012; 120(8): 1581-1588.
- 47Brodersen LE, Gerbing RB, Pardo ML, et al. Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances. 2020; 4(20): 5050-5061.
- 48Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012; 30(29): 3625-3632.
- 49Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J Clin Oncol. 2006; 24(22): 3686-3692.
- 50Van Der Velden VHJ, Van Der Sluijs-Geling A, Gibson BES, et al. Clinical significance of flow-cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia. 2010; 24(9): 1599-1606.
- 51Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11(6): 543-552.
- 52Tierens A, Bjørklund E, Siitonen S, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. British J Haematol. 2016; 174(4): 600-609.
- 53Buldini B, Rizzati F, Masetti R, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. British J Haematol. 2017; 177(1): 116-126.
- 54Sievers EL. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003; 101(9): 3398-3406.
- 55Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12): 1275-1291.
- 56Tierens A, Bjørklund E, Siitonen S, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia: results of the NOPHO-AML 2004 study. British J Haematol. 2016; 174(4): 600-609.
- 57Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. J Clin Oncol. 2006; 24(22): 3686-3692.
- 58Gibson BES, Webb DKH, Howman AJ, De Graaf SSN, Harrison CJ, Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011; 155(3): 366-376.
- 59Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005; 19(12): 2130-2138.
- 60Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008; 111(3): 1044-1053.
- 61Woods Wg, Kobrinsky N, Buckley Jd, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87(12): 4979-4989.
- 62Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC. Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer. 2018; 65(9):e27089.
- 63Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014; 32(27): 3021-3032.
- 64Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013; 31(27): 3360-3368.
- 65Getz KD, Sung L, Ky B, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children's Oncology Group. J Clin Oncol. 2019; 37(1): 12-21.
- 66Feijen EAM, Leisenring WM, Stratton KL, et al. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol. 2019; 5(6): 864-871.
- 67Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013; 122(2): 170-178.
- 68Creutzig U, Zimmermann M, Bourquin J-P, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013; 122(1): 37-43.
- 69Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012; 118(3): 761-769.
- 70Aplenc R, Meshinchi S, Sung L, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020; 105(7): 1879-1886.
- 71Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27(24): 4007-4013.
- 72Tomizawa D, Tawa A, Watanabe T, et al. Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. Leukemia. 2013; 27(12): 2413-2416.
- 73Tomizawa D, Tawa A, Watanabe T, et al. Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol. 2013; 98(5): 578-588.
- 74Entz-Werle N, Suciu S, Van Der Werff Ten Bosch J, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia. 2005; 19(12): 2072-2081.
- 75Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011; 29(3): 310-315.
- 76Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML. Blood. 2004; 120(5): 978-984.
- 77Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia. 2005; 19(12): 2117-2124.
- 78Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015; 33(27): 2949-2962.
- 79Gore L, Triche TJ, Farrar JE, et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017; 9: 108.
- 80Rasche M, Steidel E, Kondryn D, Von Neuhoff N, Sramkova L, Creutzig U, et al. Impact of a risk-adapted treatment approach in pediatric AML: a report of the AML-BFM registry 2012. Blood. 2019; 134(Supplement 1): 293.
- 81Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018; 32(10): 2167-2177.
- 82 AML_BFM_Study_Group. AIEOP-BFM AML 2020 (start QIV 2020). Available from: https://www.aml-bfm.de/studienuebersicht/aieop-bfm-aml-2020/. Accessed October 5, 2020.
- 83Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2016; 34(7): 747-755.
- 84Gale RE, Popa T, Wright M, et al. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. Blood. 2018; 131(4): 468-471.
- 85Lamba JK, Pounds S, Cao X, et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia. 2009; 23(2): 402-404.
- 86Lowis S, Lewis I, Elsworth A, et al. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British J Cancer. 2006; 95(5): 571-580.
- 87Tomizawa D, Tanaka S, Hasegawa D, et al. Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12). Japanese J Clin Oncol. 2018; 48(6): 587-593.
- 88Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: current status and future directions. Pediatr Int. 2016; 58(2): 71-80.
- 89Bolouri H, Farrar JE, Triche T, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018; 24(1): 103-112.
- 90Chaudhury S, O'connor C, Cañete A, et al. Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias. Nat Commun. 2018; 9(1): 5280.
- 91Ng SWK, Mitchell A, Kennedy JA, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016; 540(7633): 433-437.
- 92Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2): 264-278.
- 93 Administration USFaD. Midostaurin 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/midostaurin. Accessed October 5, 2020.
- 94 Administration USFaD. FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml. Accessed October 5, 2020.
- 95 Administration USFaD. FDA approves gemtuzumab ozogamicin for CD33-positive AML 2017. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml. Accessed October 5, 2020.
- 96 Administration USFaD. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed October 5, 2020.
- 97 Administration USFaD. FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation 2018. Available from: https://www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation. Accessed October 5, 2020.
- 98 Administration USFaD. FDA approves glasdegib for AML in adults age 75 or older or who have comorbidities 2018. Available from: https://www.fda.gov/drugs/fda-approves-glasdegib-aml-adults-age-75-or-older-or-who-have-comorbidities. Accessed October 5, 2020.
- 99 Administration USFaD. FDA approves venetoclax in combination for AML in adults 2018. Available from: https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults. Accessed October 5, 2020.
- 100 Administration USFaD. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia. Accessed October 5, 2020.
- 101 Administration USFaD. FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml-pediatric-patients#:~:text=On%20June%2016%2C%202020%2C%20the,patients%201%20month%20and%20older. Accessed October 5, 2020.
- 102Pearson ADJ, Zwaan CM, Kolb EA, et al. Paediatric strategy forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2020; 136: 116-129.
- 103Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2): 299-312.
- 104Ho PA, Alonzo TA, Gerbing RB, et al. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatr Blood Cancer. 2014; 61(1): 81-88.
- 105Ostronoff F, Othus M, Gerbing RB, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014; 124(15): 2400-2407.
- 106Tarlock K, Alonzo TA, Gerbing RB, et al. Distinct co-occurring mutational profiles in acute myeloid leukemia confers prognostic significance in children and young adults with FLT3/ITD mutations. Blood. 2018; 132(Supplement 1):443.
- 107Pollard JA, Alonzo TA, Brown PA, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ AML improves event-free survival and reduces relapse risk: a report from the Children's Oncology Group Protocol AAML1031. Blood. 2019; 134(Supplement_1): 292.
- 108Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377(5): 454-464.
- 109Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, et al. A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in Childhood Leukemia and Lymphoma (TACL) study. Clin Cancer Res. 2016; 22(16): 4014-4022.
- 110Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019; 381(18): 1728-1740.
- 111Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015; 16(16): 1691-1699.
- 112Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013; 31(25): 3110-3118.
- 113Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, et al. An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Blood. 2017; 130: 145.
- 114Burchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood. 2018; 132(Supplement 1): 132.
- 115Maziarz RTT, Patnaik MM, Scott BL, et al. Radius: a phase 2 randomized trial investigating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD-mutated AML. Blood. 2018; 132(Supplement 1): 662.
- 116Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014; 123(21): 3239-3246.
- 117Chen J, Glasser CL. New and emerging targeted therapies for pediatric acute myeloid leukemia (AML). Children (Basel). 2020; 7(2): 12.
- 118Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020; 10(4): 506-525.
- 119Winer ES, Stone RM. Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019; 10:2040620719860645.
- 120Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020; 21(4): 551-560.
- 121Leonti AR, Pardo L, Alonzo TA, et al. Transcriptome profiling of glycosylation genes defines correlation with E-selectin ligand expression and clinical outcome in AML. Blood. 2019; 134(Supplement_1): 3772.
- 122Deangelo DJ, Jonas BA, Liesveld JL, et al. GMI-1271), an E-selectin antagonist, improves the efficacy and safety of chemotherapy in relapsed/refractory (R/R) and newly diagnosed older patients with acute myeloid leukemia: final, correlative, and subgroup analyses. Blood. 2018; 132(Supplement 1): 331.
- 123Tarlock K, Kaeding AJ, Alonzo TA, et al. Discovery and validation of cell-surface protein mesothelin (MSLN) as a novel therapeutic target in AML: results from the COG/NCI target AML initiative. Blood. 2016; 128(22): 2873.
- 124Kaeding A, Tarlock K, Kolb EA, Meshinchi S. Immunotherapeutic targeting of mesothelin in acute myeloid leukemia in vitro with anetumab ravtansine and a novel antibody-drug conjugate. Blood. 2018; 132(Supplement 1): 1448.
- 125Gopalakrishnapillai A, Kaeding A, Schatz C, et al. In vivo evaluation of mesothelin as a therapeutic target in pediatric acute myeloid leukemia. Blood. 2019; 134(Supplement_1): 1370.
- 126Newcombe AA, Gibson BES, Keeshan K. Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Exp Hematol. 2018; 63: 1-11.
- 127Dinardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1): 7-17.
- 128Li Fu, Sutherland MK, Yu C, et al. Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia. Mol Cancer Ther. 2018; 17(2): 554-564.
- 129Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016; 127(1): 122-131.
- 130Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab, an investigational CD123 x CD3 bispecific Dart® protein, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia (AML) patients. Blood. 2019; 134(Supplement_1): 733.
10.1182/blood-2019-122073 Google Scholar
- 131Arcangeli S, Rotiroti MC, Bardelli M, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017; 25(8): 1933-1945.
- 132Gill SI. How close are we to CAR T-cell therapy for AML?. Best Pract Res Clin Haematol. 2019; 32(4):101104.
- 133Budde LE, Song J, Real MD, Kim Y, Toribio C, Wood B, et al. Abstract PR14: CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): safety and efficacy results from a phase 1 study. Cancer Immunol Res. 2020; 8(4 Supplement): PR14-PR.
- 134Thomas Ed, Buckner Cd, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977; 49(4): 511-533.
- 135Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer. 2011; 57(6): 986-992.
- 136Bresters D, Van Gils ICM, Kollen WJW, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant. 2010; 45(1): 79-85.
- 137Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011; 4(4): 437-452. quiz 53-4.
- 138Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, et al. Comparison of outcomes for pediatric patients with acute myeloid leukemia in remission and undergoing allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens based on either intravenous busulfan or total body irradiation: a report from the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(12): 2141-2147.
- 139Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, et al. Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017; 23(3): 467-474.
- 140Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia. 2003; 17(11): 2090-2096.
- 141Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer. 2010; 55(3): 414-420.
- 142Schwyzer R, Sherman GG, Cohn RJ, Poole JE, Willem P. Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21). Med Pediatr Oncol. 1998; 31(3): 144-149.
10.1002/(SICI)1096-911X(199809)31:3<144::AID-MPO3>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 143Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. J Pediatr Hematol/Oncol. 2003; 25(10): 760-768.
- 144Wayne AS, Baird K, Egeler RM. Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am. 2010; 57(1): 1-25.
- 145Song TY, Lee SH, Kim G, Baek HJo, Hwang TJu, Kook H. Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res. 2018; 53(1): 25-34.
- 146Döhner K, Paschka P. Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am Soc Hematol Educ Program. 2014; 2014(1): 34-43.
- 147Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10): 579-590.
- 148Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008; 26(35): 5797-5801.
- 149Park EuG, Yi ES, Choi YB, Sung KiW, Koo HH, Yoo KH. Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics. Pediatr Transplant. 2019; 23(4):e13397.
- 150Meybodi MA, Cao W, Luznik L, et al. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019; 3(17): 2581-2585.
- 151De Jong CN, Meijer E, Bakunina K, Nur E, Kooij MVM, de Groot MR, et al. Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors. Blood. 2019; 134(Supplement 1): 134.
- 152Gupta V, Lazarus HM, Keating A. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant. 2003; 32(10): 969-978.
- 153Nagler A, Labopin M, Beelen D, et al. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2017; 123(14): 2671-2679.
- 154Bitan M, He W, Zhang M-J, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014; 123(10): 1615-1620.
- 155Dandoy CE, Davies SM, Ahn KW, et al. Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica. 2020.
- 156Feldman EJ, Gergis U. Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?. Curr Hematol Malig Rep. 2012; 7(1): 74-77.
- 157Nagler A, Savani BN, Labopin M, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015; 2(9): e384-92.
- 158Okamoto Y, Kudo K, Tabuchi K, et al. Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplant. 2019; 54(9): 1489-1498.
- 159Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 2014; 49(5): 679-683.
- 160Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol. 2014; 93(3): 239-246.
- 161Barlogis V, Auquier P, Bertrand Y, et al. Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. Haematologica. 2015; 100(5): e186-9.
- 162Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27(9): 911-939.
- 163Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007; 25(5): 493-500.
- 164Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2015; 62(4): 704-709.
- 165Gong Q, Zhou L, Xu S, Li Xi, Zou Y, Chen J. High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials. PLoS One. 2015; 10(5):e0125612.
- 166Sung L, Aplenc R, Zaoutis T, Groll AH, Gibson B, Lehrnbecher T. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer. 2008; 51(4): 458-460.
- 167Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106(10): 2258-2266.
- 168Kavcic M, Fisher BT, Seif AE, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr. 2013; 162(6):1252-1258, 8.e1.
- 169Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018; 320(10): 995-1004.
- 170Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis. 2020; 71(1): 226-236.
- 171Egan G, Robinson PD, Martinez JPD, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med. 2019; 8(10): 4536-4546.
- 172Fisher BT, Zaoutis T, Dvorak CC, et al. Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial. JAMA. 2019; 322(17): 1673-1681.
- 173Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020:Jco2000158.
